Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KP-2033

Pembrolizumab

Home » Antibodies » Pembrolizumab

Background of Pembrolizumab

Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues and the complete folded molecule includes 4 disulfide linkages as interchain bonds and 23 interchain bonds.It was developed by Merck & Co and first approved for the treatment of metastatic malignant melanoma by the FDA on September 4, 2014, becoming the first approved therapy against PD-1. In the time since its initial approval, pembrolizumab has been granted approval in the treatment of a wide variety of cancers.

Specifications

Catalog Number:
KP-2033
Antibody Name:
Pembrolizumab
Isotype:
Human-IgG4-S228P, kappa
FC Muations:
Target:
PD1
Species Reactivity:
Human
Host Cell Line:
EXPI-CHO
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Purity:
>95% by SDS-PAGE and SEC-SEC-HPLC
Validation:
SDS-PAGE | SEC-HPLC | ELISA
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Stability:

Characterization

Application

References

  1. Longoria TC, Tewari KS: Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. Expert Opin Drug Metab Toxicol. 2016 Oct;12(10):1247-53.
  2. Poole RM: Pembrolizumab: first global approval. Drugs. 2014 Oct;74(16):1973-81. Longoria TC, Tewari KS: Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. Expert Opin Drug Metab Toxicol. 2016 Oct;12(10):1247-53.